Clinical trial
Valganciclovir to Reduce T Cell Activation in HIV Infection
NCT00264290 · University of California, San Francisco, Other · Completed
Key facts
| NCT number | NCT00264290 |
|---|---|
| Title | Valganciclovir to Reduce T Cell Activation in HIV Infection |
| Official title | Valganciclovir to Reduce T Cell Activation in HIV Infection |
| Lead sponsor | University of California, San Francisco, Other |
| Collaborators | Roche Pharma AG Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | HIV Infections, Cytomegalovirus Infections |
| Intervention type | Drug |
| Interventions | Valganciclovir, Placebo |
| Enrollment | 30 |
| Start date | Aug 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Dec 12, 2005 |
| Last update posted | Jul 31, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: